Edesa Biotech Q1 2026 Earnings Report

Edesa Biotech EPS Results

• Actual EPS: -$0.28
• Consensus EPS: -$0.28
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Edesa Biotech Revenue Results

• Actual Revenue: $0.11 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Edesa Biotech Announcement Details

• Quarter: Q1 2026
• Date: 2/13/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Edesa Biotech (NASDAQ:EDSA) is a clinical-stage biotechnology company focused on the discovery and development of next-generation vaccines and immunotherapies. The company leverages a proprietary self-amplifying RNA platform to create candidates designed for both intranasal and injectable administration. Edesa’s approach aims to elicit robust mucosal and systemic immune responses, with applications spanning infectious diseases and immuno-oncology.

Among Edesa’s pipeline programs is a lead intranasal vaccine candidate targeting SARS-CoV-2, currently advancing through early-stage clinical trials. In parallel, the company is developing therapeutic vaccine constructs to address oncoviruses and tumor-associated antigens, as well as prophylactic immunizations for broader viral threats. Edesa’s integrated research facilities in Cambridge, Massachusetts support discovery, preclinical evaluation and process development in collaboration with academic and contract manufacturing partners.

Headquartered in Cambridge, Edesa Biotech was founded by a team of immunologists and industry veterans. The company serves global markets through strategic alliances in North America, Europe and Asia. Under the leadership of CEO Steven M. Powell, PhD, Edesa is positioned to advance its pipeline toward late-stage clinical trials and to establish a differentiated platform for both infectious disease prevention and cancer immunotherapy.